Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) Net Income towards Common Stockholders: 2013-2024

Historic Net Income towards Common Stockholders for Zevra Therapeutics (ZVRA) over the last 12 years, with Dec 2024 value amounting to -$105.5 million.

  • Zevra Therapeutics' Net Income towards Common Stockholders rose 98.36% to -$544,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $35.3 million, marking a year-over-year increase of 139.40%. This contributed to the annual value of -$105.5 million for FY2024, which is 129.13% down from last year.
  • As of FY2024, Zevra Therapeutics' Net Income towards Common Stockholders stood at -$105.5 million, which was down 129.13% from -$46.0 million recorded in FY2023.
  • Zevra Therapeutics' Net Income towards Common Stockholders' 5-year high stood at -$12.8 million during FY2020, with a 5-year trough of -$105.5 million in FY2024.
  • For the 3-year period, Zevra Therapeutics' Net Income towards Common Stockholders averaged around -$64.4 million, with its median value being -$46.0 million (2023).
  • As far as peak fluctuations go, Zevra Therapeutics' Net Income towards Common Stockholders soared by 47.97% in 2020, and later crashed by 392.92% in 2021.
  • Yearly analysis of 5 years shows Zevra Therapeutics' Net Income towards Common Stockholders stood at -$12.8 million in 2020, then slumped by 392.92% to -$62.9 million in 2021, then surged by 33.95% to -$41.5 million in 2022, then dropped by 10.85% to -$46.0 million in 2023, then plummeted by 129.13% to -$105.5 million in 2024.